[go: up one dir, main page]

CL2011000672A1 - Antibody that binds to human il-17; nucleic acid encoding it; expression vector; Cellphone line; Method of production; pharmaceutical composition that includes it and its use to treat rheumatoid arthritis among other diseases. - Google Patents

Antibody that binds to human il-17; nucleic acid encoding it; expression vector; Cellphone line; Method of production; pharmaceutical composition that includes it and its use to treat rheumatoid arthritis among other diseases.

Info

Publication number
CL2011000672A1
CL2011000672A1 CL2011000672A CL2011000672A CL2011000672A1 CL 2011000672 A1 CL2011000672 A1 CL 2011000672A1 CL 2011000672 A CL2011000672 A CL 2011000672A CL 2011000672 A CL2011000672 A CL 2011000672A CL 2011000672 A1 CL2011000672 A1 CL 2011000672A1
Authority
CL
Chile
Prior art keywords
binds
antibody
diseases
human
nucleic acid
Prior art date
Application number
CL2011000672A
Other languages
Spanish (es)
Inventor
Guy Georges
Johannes Auer
Nikolaos Dimoudis
Petra Hanke
Hendrik Knoetgen
Claie Louise Langrish
Ekkehard Moessner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CL2011000672A1 publication Critical patent/CL2011000672A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Anticuerpo que se une a il-17 humana; ácido nucleico que lo codifica; vector de expresión; línea celular; método de producción; composición farmacéutica que lo comprende y su uso para tratar artritis reumatoidea entre otras enfermedades.Antibody that binds to human il-17; nucleic acid encoding it; expression vector; Cellphone line; Method of production; pharmaceutical composition that includes it and its use to treat rheumatoid arthritis among other diseases.

CL2011000672A 2008-09-29 2011-03-28 Antibody that binds to human il-17; nucleic acid encoding it; expression vector; Cellphone line; Method of production; pharmaceutical composition that includes it and its use to treat rheumatoid arthritis among other diseases. CL2011000672A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08017155 2008-09-29

Publications (1)

Publication Number Publication Date
CL2011000672A1 true CL2011000672A1 (en) 2012-03-30

Family

ID=40352697

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000672A CL2011000672A1 (en) 2008-09-29 2011-03-28 Antibody that binds to human il-17; nucleic acid encoding it; expression vector; Cellphone line; Method of production; pharmaceutical composition that includes it and its use to treat rheumatoid arthritis among other diseases.

Country Status (25)

Country Link
US (2) US8003099B2 (en)
EP (1) EP2331575B1 (en)
JP (2) JP5581323B2 (en)
KR (1) KR101318549B1 (en)
CN (2) CN102164959A (en)
AR (1) AR073692A1 (en)
AU (1) AU2009296299A1 (en)
BR (1) BRPI0919531A2 (en)
CA (1) CA2737636A1 (en)
CL (1) CL2011000672A1 (en)
CO (1) CO6351795A2 (en)
CR (1) CR20110161A (en)
EC (1) ECSP11010911A (en)
ES (1) ES2493042T3 (en)
IL (1) IL211684A0 (en)
MA (1) MA32725B1 (en)
MX (1) MX2011003184A (en)
MY (1) MY153893A (en)
NZ (1) NZ591484A (en)
PE (1) PE20110345A1 (en)
RU (1) RU2539029C2 (en)
TW (1) TWI393570B (en)
UA (1) UA103499C2 (en)
WO (1) WO2010034443A1 (en)
ZA (1) ZA201102004B (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544317A (en) 2003-07-08 2009-05-31 Genentech Inc IL-17 A/F heterologous polypeptides and therapeutic uses thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
EP2331575B1 (en) * 2008-09-29 2014-05-28 Roche Glycart AG Antibodies against human il 17 and uses thereof
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
CN104974250A (en) 2009-05-05 2015-10-14 诺维莫尼公司 Anti-il-17f antibodies and methods of use thereof
BR112012010280B1 (en) 2009-10-30 2020-09-24 Janssen Biotech, Inc. ISOLATED ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS TO HUMAN IL-17A, ITS USE, AND PHARMACEUTICAL COMPOSITION
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
BR112013002831A2 (en) 2010-08-05 2016-11-01 Anaptysbio Inc antibodies directed against il-17
RU2591083C2 (en) * 2010-10-08 2016-07-10 Новартис Аг Methods of treating psoriasis using il-17 antagonists
HUE044038T2 (en) 2010-11-05 2019-09-30 Novartis Ag Methods of treating ankylosing spondylitis using anti-il-17 antibodies
WO2012076442A1 (en) 2010-12-07 2012-06-14 F. Hoffmann-La Roche Ag Adapter for the non-invasive cultivation of cells and uses thereof
BR112013009934A2 (en) 2010-12-07 2016-07-05 Hoffmann La Roche device for adding at least two feed solutions, cell culture device, use of a device and method for obtaining a polypeptide
TW201307845A (en) * 2010-12-13 2013-02-16 Novartis Ag Predictive methods and methods of treating arthritis using IL-17 antagonists
CN102188707B (en) * 2011-02-25 2015-08-05 中国医学科学院基础医学研究所 The purposes of IL-17 inhibitor in the medicine of preparation treatment influenza
PL2686334T5 (en) 2011-03-16 2020-10-19 F.Hoffmann-La Roche Ag Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
AU2012341081B2 (en) 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
CN104244979A (en) 2012-04-20 2014-12-24 诺华股份有限公司 Methods of treating ankylosing spondylitis using IL-17 antagonists
CA2886207C (en) 2012-09-26 2021-01-05 Jorg Wischhusen Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
EP2953969B1 (en) * 2013-02-08 2019-08-28 Novartis AG Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
KR20210157418A (en) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
MX375889B (en) * 2013-11-18 2025-03-06 Shanghai hengrui pharmaceutical co ltd IL-17A BINDING AGENT AND ITS USES.
US20160340422A1 (en) * 2014-01-28 2016-11-24 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
HUE064573T2 (en) 2014-03-26 2024-03-28 Univ Wuerzburg J Maximilians Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
DK3191120T3 (en) 2014-09-10 2024-07-15 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in patients with psoriatic arthritis
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
CN107407677B (en) * 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 Gene expression signatures and treatments for multiple sclerosis
CN108251431B (en) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 Double-carrier system and application thereof
FI3356827T3 (en) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
FI3355919T3 (en) 2015-10-02 2023-01-13 Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
ES2992409T3 (en) 2016-07-19 2024-12-12 Novartis Ag Treatment methods for new-onset plaque psoriasis using IL-17 antagonists
CN109715660A (en) 2016-09-14 2019-05-03 北京韩美药品有限公司 A kind of antibody and its function fragment that can specifically combine IL-17A
US10322174B2 (en) 2016-10-26 2019-06-18 Cedars-Sinai Medical Center Neutralizing anti-TL1A monoclonal antibodies
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
CN109206515B (en) * 2017-07-06 2021-10-12 北京伟峰益民科技有限公司 Fully human anti-human interleukin 17A antibody and application thereof
CN111344043A (en) 2017-11-02 2020-06-26 诺华股份有限公司 Methods of treating tendinopathy using interleukin-17 (IL-17) antagonists
KR102048475B1 (en) * 2017-11-10 2019-11-26 주식회사 와이바이오로직스 Antibodies Specifically Binding Against IL-17A and Uses Thereof
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
CN113603776B (en) * 2018-02-12 2022-10-21 原启生物科技(上海)有限责任公司 IL17 antibodies and uses thereof
CA3098374A1 (en) 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
JP6930778B2 (en) * 2018-05-17 2021-09-01 江蘇▲筌▼信生物医薬有限公司Ｑｙｕｎｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． Anti-human interleukin 17A monoclonal antibody and its use
KR20210122243A (en) 2019-01-31 2021-10-08 누맙 세러퓨틱스 아게 Multispecific antibodies having specificity for LNF and L-17A, antibodies targeting LLA-17A, and methods of using the same
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
JP2022549200A (en) 2019-09-20 2022-11-24 ノバルティス アーゲー Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
JP7504992B2 (en) 2019-10-24 2024-06-24 プロメテウス バイオサイエンシーズ，インク． Humanized antibodies against TNF-like ligand 1A (TL1A) and uses thereof
AR121183A1 (en) 2019-11-19 2022-04-27 Novartis Ag TREATMENT METHODS FOR LUPUS NEPHRITIS WITH INTERLEUKIN-17 ANTAGONISTS (IL-17)
JP2023504679A (en) 2019-12-06 2023-02-06 ノバルティス アーゲー Methods of treating lichen planus using interleukin-17 (IL-17) antagonists
AU2023272370A1 (en) 2022-05-16 2025-01-02 Albert-Ludwigs-Universität Freiburg Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
CN119925593A (en) * 2023-06-05 2025-05-06 北京东方百泰生物科技股份有限公司 A pharmaceutical preparation of anti-IL-11 monoclonal antibody

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US5716623A (en) 1994-12-07 1998-02-10 Immunex Corporation Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules
JP3253633B2 (en) 1995-10-27 2002-02-04 シェーリング コーポレイション Novel use of mammalian CTLA-8 and related drugs
US6063372A (en) 1995-10-27 2000-05-16 Inserm, Institut National De La Sante Et De La Recherche Medicale Uses of mammalian CTLA-8 and related reagents
US6271014B1 (en) 1998-01-09 2001-08-07 Schering-Plough Mammalian proteinases; related reagents and methods
US6333345B1 (en) 1999-05-14 2001-12-25 Sepracor, Inc. Methods of using and compositions comprising N-desmethylzolpidem
CN1341660A (en) * 2000-09-07 2002-03-27 上海博德基因开发有限公司 A novel polypeptide-human interleukin receptor-ligand (IL-17B and IL17BR) 32.56 and polynucleotide for coding said polypeptide
AU2004292393C1 (en) 2003-11-21 2011-08-04 Ucb Pharma S.A. Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL2481753T3 (en) * 2005-12-13 2018-09-28 Eli Lilly And Company Anti-IL-17 Antibodies
WO2007117749A2 (en) * 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
WO2008002115A1 (en) 2006-06-27 2008-01-03 Vladimir Guzenko Diaphragm hydrounit for converting gravitational force into a torque for a fuel-less engine and said engine
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
MX2009001620A (en) * 2006-08-11 2009-02-23 Schering Corp Antibodies to il-17a.
EP2331575B1 (en) * 2008-09-29 2014-05-28 Roche Glycart AG Antibodies against human il 17 and uses thereof

Also Published As

Publication number Publication date
CN102164959A (en) 2011-08-24
CA2737636A1 (en) 2010-04-01
RU2539029C2 (en) 2015-01-10
HK1171458A1 (en) 2013-03-28
CN102617735B (en) 2015-09-09
US20100080812A1 (en) 2010-04-01
PE20110345A1 (en) 2011-06-13
MX2011003184A (en) 2011-04-21
CN102617735A (en) 2012-08-01
CO6351795A2 (en) 2011-12-20
CR20110161A (en) 2011-04-27
EP2331575A1 (en) 2011-06-15
IL211684A0 (en) 2011-06-30
MY153893A (en) 2015-04-15
ECSP11010911A (en) 2011-05-31
KR101318549B1 (en) 2013-10-16
US20130195844A1 (en) 2013-08-01
TW201023882A (en) 2010-07-01
NZ591484A (en) 2012-09-28
JP2014128279A (en) 2014-07-10
JP2012503977A (en) 2012-02-16
EP2331575B1 (en) 2014-05-28
ES2493042T3 (en) 2014-09-11
JP5581323B2 (en) 2014-08-27
KR20110048572A (en) 2011-05-11
AU2009296299A1 (en) 2010-04-01
ZA201102004B (en) 2011-12-28
RU2011116927A (en) 2012-11-10
MA32725B1 (en) 2011-10-02
TWI393570B (en) 2013-04-21
UA103499C2 (en) 2013-10-25
AR073692A1 (en) 2010-11-24
WO2010034443A1 (en) 2010-04-01
BRPI0919531A2 (en) 2015-12-08
US8003099B2 (en) 2011-08-23

Similar Documents

Publication Publication Date Title
CL2011000672A1 (en) Antibody that binds to human il-17; nucleic acid encoding it; expression vector; Cellphone line; Method of production; pharmaceutical composition that includes it and its use to treat rheumatoid arthritis among other diseases.
CL2007001840A1 (en) Neutralizing antibody that binds to human interleukin 17 (il-17); DNA sequence encoding it; vector and host cell that comprise it; production process; pharmaceutical preparation that includes it; and its use for the treatment or prophylaxis of pathologies mediated by il-17.
CL2008002444A1 (en) Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
CL2011002482A1 (en) Bispecific antibody that specifically binds to human erbb-3 and human c-met proteins; nucleic acid encoding it; pharmaceutical composition that includes it; and its use to treat cancer
CL2013001279A1 (en) Isolated human antibody or antigen binding fragment thereof that specifically binds and neutralizes the activity of the human tnf-type ligand 1a (htl1a); nucleic acid molecule that encodes it; expression vector; Method of production; pharmaceutical composition that includes it; And its use.
CL2011001994A1 (en) Antagonist antibody that binds to human ox40 protein; DNA sequence encoding it; cloning or expression vector comprising said coding DNA; host cell comprising said cloning or expression vector; production process of said antibody; pharmaceutical composition comprising said antibody; medical use of said antibody; fusion protein comprising said antibody.
CL2009000459A1 (en) Antibody binds to rgm a protein; nucleic acid that encodes it; vector; host cell; Method of production; pharmaceutical composition comprising it; antibody construct comprising said protein; antibody conjugate comprising the construct; use.
CL2011002611A1 (en) Isolated anti-cadherin-17 antibody; nucleic acid molecule that encodes it; vector; host cell; Method of production; immunoconjugate that understands it; composition that includes it; and its use to treat or prevent a disease associated with target cells expressing cadherin-17.
CL2013000566A1 (en) Antigen binding protein that binds her3; nucleic acid encoding it; expression vector; recombinant host cell; Method of production; pharmaceutical composition that includes it; and its use to treat cancer.
PE20161327A1 (en) BINDING PROTEINS TO THE HUMAN IL-23 ANTIGEN
CL2012000524A1 (en) Humanized antibody that binds to human cdcp1 useful in the treatment of cancer; pharmaceutical composition; nucleic acid, expression vector and host cell comprising it; and method of producing the antibody.
CL2011002360A1 (en) Anti-alpha5beta1 antibody; nucleic acid molecule encoding the antibody; host cell; method for producing anti-alpha5 beta1 antibodies; immunoconjugate comprising the antibody; pharmaceutical composition
CL2012001547A1 (en) Human csf-1r binding antibody; pharmaceutical composition comprising it; nucleic acid that encodes it; recombinant expression vector; transformed prokaryotic or eukaryotic cell; Method of production; and its use to treat cancer.
CL2007002987A1 (en) ANTI-NOTCH3 ANTIBODIES; NUCLEIC ACID CODING THEM; VECTOR AND CELL THAT UNDERSTANDS IT; METHOD OF PRODUCTION; AND ITS USE TO TREAT DISEASES RELATED TO NOTCH3.
CL2013001468A1 (en) Isolated human antibody that specifically binds to the human glucagon receptor or antigen binding fragment thereof; nucleic acid molecule that encodes it; expression vector; Method of production; pharmaceutical composition that includes it; and its use to treat a disease or condition associated with high blood glucose or ketone levels.
CL2017000772A1 (en) Isolated antibody that binds to mesothelin; nucleic acid encoding it; host cell; Method of production; immunoconjugate; pharmaceutical formulation that comprises it; its use to treat cancer; and method of detection of human mesothelin. (divisional application 1776-2013)
PE20170772A1 (en) MONOCLONAL ANTI-CTLA4 ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT, A PHARMACEUTICAL COMPOSITION AND USE
CL2013001625A1 (en) Binding protein that specifically binds to tnf-alpha; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical composition that includes it; and its use to treat a disease or disorder associated with tnf-alpha.
CL2011002039A1 (en) Humanized antibody that binds to human cd19; isolated nucleic acid encoding said antibody; vector and host cell; composition and immunoconjugate; method to inhibit the growth of tumor cells expressing cd19.
CL2016002116A1 (en) Anti-fap antibodies and methods of use (divisional sol. N ° 369-13).
AR068861A1 (en) ANTIBODIES THAT JOIN IL-4 AND / OR IL-13 AND ITS USES
CL2008000935A1 (en) Anti-ige human monoclonal antibody or fragment thereof; nucleic acid encoding it; vector and host cell; Preparation method; pharmaceutical composition that includes it; and its use in the treatment of disorders related to ige.
BRPI0807710A8 (en) ANTIBODIES THAT BIND HUMAN IL-23P19 AND IL-23, ANTIBODY, ISOLATED NUCLEIC ACID, EXPRESSION VECTOR, MICROBIAL HOST CELL, METHOD OF PRODUCTION OF A POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION
CL2015003090A1 (en) Specific binding proteins and their uses.
CL2011002756A1 (en) Antibody that binds to human or cynomolgus complement protein c3b; pharmaceutical composition, nucleic acid, vector and host cell comprising said antibody; use to treat age-related macular degeneration.